Targeting Gynecologic Malignancy: Precision Molecular Pathology of Uterine Cancer
Historically, uterine cancers were classified broadly as either Type I (estrogen-dependent) or Type II (aggressive, estrogen-independent), leading to a “one-size-fits-all” approach to surgery and chemotherapy. This rudimentary classification is obsolete. Precision Molecular Pathology of Uterine Cancer (Molecular Pathology Library) is the definitive, fiercely advanced text that redefines endometrial and cervical malignancies based on their unique genomic signatures. This volume provides the exact blueprints required by oncologists and molecular pathologists to classify tumors accurately and select the highly targeted therapies that dramatically improve patient survival.
Mastering the Genomic Landscape of Endometrial Cancer
The core philosophy of this text is personalized oncology. The authors aggressively detail the Cancer Genome Atlas (TCGA) classification system for endometrial carcinoma. It dictates exactly how to utilize molecular testing to categorize tumors into four distinct prognostic groups: POLE-mutated, mismatch repair deficient (MSI-high), copy-number low, and copy-number high (serous-like). It provides the crucial understanding of why a patient with a POLE mutation has an excellent prognosis despite ugly histology, drastically altering their need for toxic adjuvant therapy.
Navigating Cervical Neoplasia and Targeted Inhibitors
The book provides a masterclass in molecular therapeutics. It dictates the exact clinical pathways for integrating HPV genotyping and biomarker analysis into the management of cervical cancer. It provides exhaustive reviews of emerging targeted therapies, detailing the rationale behind using PARP inhibitors, immune checkpoint inhibitors (like pembrolizumab), and targeted kinase inhibitors based on the specific molecular derangements identified in the patient’s tumor tissue.
Frequently Asked Questions (FAQs)
Is this book relevant for standard surgical pathologists?
Absolutely. It details exactly which immunohistochemical surrogates (like p53 and mismatch repair proteins) surgical pathologists must run on routine biopsies to approximate the expensive TCGA genomic classification.
Who is the primary audience?
It is the absolute, mandatory reference for Gynecologic Oncologists, Molecular Pathologists, Surgical Pathologists, and Oncology Researchers.
